Compounds > omadacycline
Page last updated: 2024-11-13

omadacycline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

omadacycline: demonstrated in vitro activity against a broad range of Gram-positive and select Gram-negative pathogens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54697325
CHEMBL ID1689772
CHEBI ID177758
SCHEMBL ID1525961
SCHEMBL ID17150976
SCHEMBL ID20952297
MeSH IDM000598114

Synonyms (52)

Synonym
CHEBI:177758
(4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[(2,2-dimethylpropyl)amino]methyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
ptk 0796, bay 73-6944
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropylamino)methyl]-3,10,12,12a-tetrahydroxy-1,11-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide
mk-2764
bay-73-7388
bay-73-6944
ptk-0796
amadacycline
ptk-796
omadacycline
ptk 0796
bay 73-6944
CHEMBL1689772
D09647
389139-89-3
omadacycline (usan)
090ip5rv8f ,
nuzyra
omadacycline [usan:inn]
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-(((2,2- dimethylpropyl)amino)methyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a- tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-9-(((2,2-dimethylpropyl)amino)methyl)- 3,10,12,12a- tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2- carboxamide
unii-090ip5rv8f
HY-14865
CS-1338
omadacycline [inn]
2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-(((2,2-dimethylpropyl)amino)methyl)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4s,4as,5ar,12as)-
omadacycline [usan]
omadacycline [mi]
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-9-(((2,2-dimethylpropyl)amino)methyl)-3,10,12,12a- tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
omadacycline [who-dd]
SCHEMBL1525961
AC-33245
SCHEMBL17150976
DB12455
NCGC00378946-03
389139-89-3 (free base)
9-neopentylaminomethylminocycline
U3B ,
SCHEMBL20952297
BCP12946
Q15426992
ptk 0796;amadacycline
ptk0796
gtpl10839
compound 6 [pmid: 21302930]
EX-A4252
E80520
DTXSID201027687
EN300-20385155
(4s,4as,5ar,12as)-4,7-bis(dimethylamino)-9-{[(2,2-dimethylpropyl)amino]methyl}-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

Research Excerpts

Overview

Omadacycline is a novel aminomethylcycline tetracyCline antimicrobial that was approved for the treatment of community-associated bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in 2018. It has been demonstrated to have potent anti-NTM effects and clinical efficacy against MABC, including M. tuberculosis.

ExcerptReferenceRelevance
"Omadacycline is a novel third-generation member of the tetracycline family of antibacterials that has recently been demonstrated to have potent anti-NTM effects and clinical efficacy against MABC, including M."( Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.
Moniri, NH; Rizzo, AR, 2022)		2.89
"Omadacycline is a novel aminomethylcycline tetracycline antimicrobial that was approved for the treatment of community-associated bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in 2018. "( Antimicrobial susceptibility of Clostridioides difficile to omadacycline and comparator antimicrobials.
Cheknis, A; Johnson, S; Petrella, LA; Skinner, AM, 2023)		2.6
"Omadacycline is a new analog of the tetracycline class active against atypical bacteria, as well as against staphylococci, including methicillin-resistant strains, and "( The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP).
Cilloniz, C; Torres, A, 2023)		2.63
"Omadacycline is a broad-spectrum intravenous and oral tetracycline antibiotic approved for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. "( Compatibility of Omadacycline With Select Parenteral Products in Simulated Y-site Administration.
Butler, DA; Gifford, M; McCray, D; Moolick, K, 2023)		2.69
"Omadacycline is a novel tetracycline antibiotic that exhibits good "( Case Report: Omadacycline in the treatment of macrolide-unresponsive
Fang, C; Xu, L, 2023)		2.72
"Omadacycline is an aminomethylcycline antibiotic with "(
Dubois, J; Dubois, M; Martel, JF, 2020)		2
"Omadacycline is a once-daily oral or intravenous (i.v.) aminomethylcycline antibiotic approved in the United States for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. "( An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline.
Kovacs, SJ; Praestgaard, J; Stein, DS; Sun, H; Sunkara, G; Tanaka, SK; Ting, L; Villano, S, 2020)		2.21
"Omadacycline is a semisynthetic aminomethylcycline antibacterial derived from the tetracycline class. "( The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study.
Bai, S; Chitra, S; Hunt, TL; Manley, A; McGovern, PC; Tzanis, E, 2021)		2.28
"Omadacycline is a novel aminomethylcycline antimicrobial agent that is available in both oral and intravenous formulations. "( Return of the tetracyclines: omadacycline, a novel aminomethylcycline antimicrobial.
Childs-Kean, LM; Cho, JC; Crotty, MP; Zmarlicka, MT, 2018)		2.21
"Omadacycline is a novel aminomethylcycline approved for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. "( Omadacycline Enters the Ring: A New Antimicrobial Contender.
Barber, KE; Bell, AM; Stover, KR; Wagner, JL; Wingler, MJB, 2018)		3.37
"Omadacycline is an aminomethylcycline derived from the tetracycline class. "( Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants.
Fluit, AC; van Gorkum, S; Vlooswijk, J, 2019)		2.23
"Omadacycline is an alternative treatment option for ABSSSI and CABP."( Omadacycline: A New Tetracycline Antibiotic.
Chahine, EB; Dougherty, JA; Shihadeh, KC; Sucher, AJ, 2019)		3.4
"Omadacycline is a semisynthetic aminomethylcycline antibacterial derived from the tetracycline class of antibiotics that is unaffected by these resistance mechanisms."( Omadacycline: A Modernized Tetracycline.
Gallagher, JC, 2019)		2.68
"Omadacycline is a semisynthetic tetracycline antibiotic. "( An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic.
Chitra, S; File, TM; McGovern, PC; Opal, S; Tzanis, E; van der Poll, T, 2019)		2.24
"Omadacycline is a novel aminomethylcycline antimicrobial and semisynthetic derivative of tetracycline. "( Microbiology and Preclinical Review of Omadacycline.
Karlowsky, JA; Steenbergen, J; Zhanel, GG, 2019)		2.23
"Omadacycline is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. "( Mechanism of action of the novel aminomethylcycline antibiotic omadacycline.
Donatelli, J; Draper, MP; Levy, SB; Macone, A; Tanaka, SK; Trieber, CA; Weir, S, 2014)		2.08
"Omadacycline is a first-in-class aminomethylcycline antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative aerobes and anaerobes and atypical bacterial pathogens. "( In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline.
Tanaka, SK; Villano, S, 2016)		2.12
"Omadacycline is a first-in-class aminomethylcycline antibiotic that circumvents common tetracycline resistance mechanisms. "( Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.
Loh, E; Steenbergen, J; Villano, S, 2016)		3.32
"Omadacycline is a first-in-class aminomethylcycline antibiotic with microbiological activity against Gram-positive and Gram-negative aerobes and anaerobes and atypical bacteria that is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). "( Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.
Kovacs, SJ; Kuemmell, A; Machineni, S; Praestgaard, J; Stein, DS; Sun, H; Sunkara, G; Tanaka, SK; Ting, L; Villano, S, 2016)		2.09

Effects

Omadacycline has been recently FDA-approved for community-acquired bacterial pneumonia and acute bacterial skin and skin-structure infections. The drug has been found to have potent activity against antibiotic-resistant pathogens.

ExcerptReferenceRelevance
"Omadacycline has been recently FDA-approved for community-acquired bacterial pneumonia and acute bacterial skin and skin-structure infections. "( Investigating the immunomodulatory activities of omadacycline.
Bryant, AE; Stevens, DL, 2022)		2.42
"Omadacycline has been found to have potent activity against antibiotic-resistant pathogens including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, extended spectrum beta-lactamase-producing Escherichia coli and multidrug-resistant Streptococcus pneumoniae."( Return of the tetracyclines: omadacycline, a novel aminomethylcycline antimicrobial.
Childs-Kean, LM; Cho, JC; Crotty, MP; Zmarlicka, MT, 2018)		1.49

Actions

Omadacycline displays a comparable efficacy and safety profile to standard-of-care agents. The most common side effects observed were gastrointestinal.

ExcerptReferenceRelevance
"Omadacycline displays a comparable efficacy and safety profile to standard-of-care agents, with the most common side effects observed being gastrointestinal."( Omadacycline Enters the Ring: A New Antimicrobial Contender.
Barber, KE; Bell, AM; Stover, KR; Wagner, JL; Wingler, MJB, 2018)		2.64
"Omadacycline displays in vitro activity against a wide range of bacteria. "( Omadacycline: A New Tetracycline Antibiotic.
Chahine, EB; Dougherty, JA; Shihadeh, KC; Sucher, AJ, 2019)		3.4

Treatment

ExcerptReferenceRelevance
"The Omadacycline for Pneumonia Treatment In the Community (OPTIC) phase III study demonstrated noninferiority of omadacycline to moxifloxacin using this endpoint."( Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.
Chitra, S; Curran, M; Kirsch, C; Manley, A; McGovern, PC; Noble, R; Ramirez, JA; Tzanis, E, 2019)		0.99

Toxicity

ExcerptReferenceRelevance
" The most common treatment-emergent adverse events were gastrointestinal (including nausea [60% to 73%] and vomiting [20% to 40%]) and were generally mild and transient."( Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study.
Bai, S; Bhiwandi, P; Chitra, S; Garrity-Ryan, L; Manley, A; Overcash, JS; Steenbergen, J; Tzanis, E, 2019)		0.77
" Similar to most tetracyclines, transient nausea and vomiting and low-magnitude increases in liver aminotransferases were the most frequent treatment-emergent adverse events in phase III studies but were not treatment limiting."( An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic.
Chitra, S; File, TM; McGovern, PC; Opal, S; Tzanis, E; van der Poll, T, 2019)		0.8
" The primary outcome was the clinical response rate at the posttreatment evaluation, whereas the secondary outcomes were risk of an adverse event (AE) and mortality."( The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials.
Chang, SP; Chao, CM; Lai, CC; Lan, SH; Lu, LC, 2019)		0.81
" Safety monitoring included the collection of adverse events (AEs), performance of laboratory tests, determination of vital signs, and performance of electrocardiograms."( An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline.
Kovacs, SJ; Praestgaard, J; Stein, DS; Sun, H; Sunkara, G; Tanaka, SK; Ting, L; Villano, S, 2020)		0.76
" Safety was evaluated as treatment-emergent adverse events (TEAEs) and laboratory measures."( Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
Chitra, S; Cornely, OA; File, TM; Garrity-Ryan, L; McGovern, PC; Noble, R, 2021)		0.93
" Safety was assessed by treatment-emergent adverse events and laboratory measures."( Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections.
Chitra, S; McGovern, PC; Pai, MP; Wilcox, MH, 2021)		0.93
" Safety evaluations included treatment-emergent adverse events and laboratory measures."( Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.
Chitra, S; McGovern, P; Pai, MP; Wilcox, M, 2021)		0.93

Pharmacokinetics

We assessed the plasma and soft-tissue pharmacokinetic exposure of omadacycline in infected patients with diabetic foot infection (DFI) and healthy volunteers using in vivo microdialysis. We evaluated the effect of a potential drug-drug interaction of verapamil-a known P-glycoprotein (P-gp) inhibitor-with omad Tracycline.

ExcerptReferenceRelevance
" Low protein binding (21%), large volume of distribution (190 L), low systemic clearance (10 L/hour), and long elimination half-life (16-17 hours) support once-daily dosing."( Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline.
Pai, MP; Rodvold, KA, 2019)		0.75
" A previously developed population pharmacokinetic (PK) model based on phase 1 intravenous and oral PK data was refined using data from infected patients."( Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data.
Ambrose, PG; Bhavnani, SM; Friedrich, L; Lakota, EA; Rubino, CM; Safir, MC; Steenbergen, JN; Trang, M; Tzanis, E; Van Wart, SA, 2020)		0.83
"This phase I, open-label study evaluated the effect of a potential drug-drug interaction of verapamil-a known P-glycoprotein (P-gp) inhibitor-with omadacycline on the pharmacokinetic profile of omadacycline in healthy adults."( The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study.
Bai, S; Chitra, S; Hunt, TL; Manley, A; McGovern, PC; Tzanis, E, 2021)		1.04
"3%) of the 12 participants enrolled in the study completed the study, and all enrolled participants were included in the safety and pharmacokinetic populations."( The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study.
Bai, S; Chitra, S; Hunt, TL; Manley, A; McGovern, PC; Tzanis, E, 2021)		0.84
"An in vitro dilutional pharmacokinetic model was used."( In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii.
Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2021)		0.91
"We assessed the plasma and soft-tissue pharmacokinetic exposure of omadacycline in infected patients with diabetic foot infection (DFI) and healthy volunteers using in vivo microdialysis."( Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis.
Fratoni, AJ; Gill, CM; Kuti, JL; Nicolau, DP; Shepard, AK, 2022)		2.4
" Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities."( Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics.
Bhavnani, SM; Friedrich, L; Lakota, EA; McGovern, PC; Rubino, CM; Safir, MC; Steenbergen, JN; Trang, M; Tzanis, E, 2023)		1.17

Bioavailability

ExcerptReferenceRelevance
" Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens."( Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
Achorn, C; Chen, CL; Clark, RB; Deng, Y; Fyfe, C; Grossman, TH; He, M; Hogan, PC; Hunt, DK; O'Brien, WJ; Plamondon, L; Rönn, M; Sutcliffe, JA; Xiao, XY; Zhu, Z, 2012)		0.38
" The bioavailability of a phase 3 tablet formulation relative to that obtained via intravenous (i."( Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.
Kovacs, SJ; Kuemmell, A; Machineni, S; Praestgaard, J; Stein, DS; Sun, H; Sunkara, G; Tanaka, SK; Ting, L; Villano, S, 2016)		0.65
" Oral omadacycline bioavailability is 34."( Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline.
Pai, MP; Rodvold, KA, 2019)		1.24
" A food effect on oral bioavailability was included in the model."( Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data.
Ambrose, PG; Bhavnani, SM; Friedrich, L; Lakota, EA; Rubino, CM; Safir, MC; Steenbergen, JN; Trang, M; Tzanis, E; Van Wart, SA, 2020)		0.83

Dosage Studied

Omadacycline offers once daily oral and IV dosing and a clinical tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections.

ExcerptRelevanceReference
" Omadacycline offers once daily oral and IV dosing and a clinical tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections where resistance has rendered many less effective."( Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Steenbergen, J; Tanaka, SK; Villano, S, 2016)		1.6
" Analyses of subgroups of patients from this trial showed similar activity to that of the comparator drug, good safety and no dosage adjustments for age, sex or hepatic or renal impairment."( The role of omadacycline in skin and soft tissue infections.
Montravers, P; Tanaka, S; Tran-Dinh, A, 2018)		0.86
" Dosage adjustments are not required for patients with renal impairment."( Omadacycline Enters the Ring: A New Antimicrobial Contender.
Barber, KE; Bell, AM; Stover, KR; Wagner, JL; Wingler, MJB, 2018)		1.92
" No dosage adjustment is needed in patients with renal or hepatic impairment."( Omadacycline: A New Tetracycline Antibiotic.
Chahine, EB; Dougherty, JA; Shihadeh, KC; Sucher, AJ, 2019)		1.96
" The final population PK model was a three-compartment model with first-order absorption using transit compartments to account for absorption delay following oral dosing and first-order elimination."( Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data.
Ambrose, PG; Bhavnani, SM; Friedrich, L; Lakota, EA; Rubino, CM; Safir, MC; Steenbergen, JN; Trang, M; Tzanis, E; Van Wart, SA, 2020)		0.83
" coli fAUC/MIC targets align with in vivo data and will be useful in determining omadacycline dosing for this pathogen."( In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii.
Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR, 2021)		1.14
"Many antibiotics require dosage adjustments in patients with renal impairment."( Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
Chitra, S; Cornely, OA; File, TM; Garrity-Ryan, L; McGovern, PC; Noble, R, 2021)		0.93
" The oral-only dosing regimens provide the potential for treatment of CABP and ABSSSI either within a hospital setting or in the community, which could support earlier hospital discharge and reduced treatment costs."( Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
Amodio-Groton, M; Leviton, IM, 2022)		2.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tetracyclinesA subclass of polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (70)

Assay IDTitleYearJournalArticle
AID1328991Antibacterial activity against Salmonella sp.2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329052Induction of CYP2C8 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329004Antibacterial activity against Clostridium difficile infected in hamster model assessed as median survival time2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID587830Antibacterial activity against wild type Staphylococcus aureus Smith ATCC 13709 by CLSI M07-A8 method2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1329002Antibacterial activity against Clostridium perfringens2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID587837Antibacterial activity against Klebsiella pneumoniae ATCC 13883 by CLSI M07-A8 method2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1329015Antibacterial activity against Streptococcus pneumoniae PBS13992016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329020Antibacterial activity against Haemophilus influenzae PBS981 infected in CD-1 mouse assessed as reduction in bacterial load in lungs administered intravenously as single dose after 2 hrs of infection measured after 24 hrs post treatment2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329012Inhibition of human ERG2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329055Induction of CYP2D6 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328995Antibacterial activity against Proteus sp.2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328987Antibacterial activity against Escherichia coli2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329003Bacteriostatic activity against Haemophilus influenzae assessed as reduction in bacterial load at MIC by time-kill analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID671548Antibacterial activity against tetracycline-susceptible Staphylococcus aureus ATCC 13709 Smith isolate SA1002012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID587836Antibacterial activity against tetracycline-resistant Escherichia coli isolate 155 harboring tet(A) gene by CLSI M07-A8 method2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1328989Antibacterial activity against Enterobacter cloacae2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328985Antibacterial activity against Haemophilus influenzae2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329005Metabolic stability in human microsomes at 4.8 uM after 30 mins2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID671550Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate SA158 expressing TetK gene2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID1329019Antibacterial activity against Haemophilus influenzae PBS9812016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID587832Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate 158 harboring tet(K) gene by CLSI M07-A8 method2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1329017Antibacterial activity against Staphylococcus aureus USA400 in mouse thigh wound infection model assessed as reduction in bacterial load administered intravenously as single dose after 2 hrs of infection measured after 24 hrs post treatment2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329014Antibacterial activity against Staphylococcus aureus USA4002016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329051Induction of CYP2B6 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329000Antibacterial activity against Clostridium difficile by broth microdilution assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329013Antibacterial activity against Staphylococcus aureus USA3002016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328994Antibacterial activity against Pseudomonas aeruginosa2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328990Antibacterial activity against Serratia marcescens2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328999Antibacterial activity against Haemophilus influenzae by microdilution broth assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329016Antibacterial activity against Staphylococcus aureus USA300 in mouse thigh wound infection model assessed as reduction in bacterial load administered intravenously as single dose after 2 hrs of infection measured after 24 hrs post treatment2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID671557Antibacterial activity against Staphylococcus aureus ATCC 13709 infected in CD-1 mouse assessed as increase in survival at 30 mg/kg, po administered as single dose 1 hr post infection measured after 48 hrs post infection2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID671553Antibacterial activity against Escherichia coli ATCC 25922 isolate 1072012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID1329054Induction of CYP2C19 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329057Induction of CYP2J2 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329049Induction of CYP1B1 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329050Induction of CYP2A6 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID671560Oral bioavailability in rat2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID671558Antibacterial activity against Staphylococcus aureus ATCC 13709 infected in po dosed CD-1 mouse assessed as increase in survival administered as single dose 1 hr post infection measured after 48 hrs post infection2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID1329001Antibacterial activity against Clostridium difficile by agar microdilution assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328993Antibacterial activity against Stenotrophomonas maltophilia2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID671556Antibacterial activity against Staphylococcus aureus ATCC 13709 infected in CD-1 mouse assessed as increase in survival at 3 mg/kg, iv administered as single dose 1 hr post infection measured after 48 hrs post infection2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID1329058Induction of CYP3A4/5 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID671552Antibacterial activity against tetracycline-resistant Streptococcus pneumoniae isolate 160 expressing tetM gene2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID671551Antibacterial activity against Streptococcus pneumoniae ATCC 49619 isolate 1062012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID671554Antibacterial activity against Escherichia coli isolate EC155 expressing tetA gene2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID1329006Metabolic stability in human hepatocytes at 48 uM up to 24 hrs2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328988Antibacterial activity against Enterobacter aerogenes2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329053Induction of CYP2C9 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID587835Antibacterial activity against Escherichia coli ATCC 25922 by CLSI M07-A8 method2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1329056Induction of CYP2E1 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328998Antibacterial activity against Klebsiella pneumoniae by microdilution broth assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328997Antibacterial activity against Escherichia coli by microdilution broth assay2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID587833Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by CLSI M07-A8 method2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1329048Antibacterial activity against Bacteroides fragilis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID671549Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate SA161 expressing TetM gene2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID671694Oral bioavailability in human2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID587834Antibacterial activity against tetracycline-resistant Streptococcus pneumoniae isolate 160 harboring tet(M) gene by CLSI M07-A8 method2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1328992Antibacterial activity against Shigella sp.2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID587831Antibacterial activity against tetracycline-resistant Staphylococcus aureus isolate 161 harboring tet(M) gene by CLSI M07-A8 method2011Journal of medicinal chemistry, Mar-10, Volume: 54, Issue:5
8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.
AID1328996Antibacterial activity against Providencia sp.2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329008Induction of CYP1A1 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329007Induction of CYP1A2 mRNA level in human primary hepatocytes at 1 to 100 uM after 24 to 48 hrs relative to control2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1328986Antibacterial activity against Moraxella catarrhalis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1329018Antibacterial activity against Streptococcus pneumoniae PBS1399 infected in mouse assessed as protection against bacterial infection by measuring mouse survival administered intravenously as single dose after 2 hrs of infection measured on day 72016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID671555Antibacterial activity against Klebsiella pneumoniae ATCC 138832012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID671559Oral bioavailability in CD1 mouse at 30 mg/kg2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's43 (42.57)24.3611
2020's58 (57.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.32 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index99.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (11.76%)5.53%
Reviews22 (21.57%)6.00%
Case Studies2 (1.96%)4.05%
Observational0 (0.00%)0.25%
Other66 (64.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
carbamates
[no description available]		2.2510amino-acid anion
bumetanide
[no description available]		2.610amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		8.711aromatic ether;
nitrile;
polyether;
tertiary amino compound
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		3.2310aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
furosemide
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.		2.610chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		2.4110C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
potassium chloride
Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.		2.610inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
carbachol
Carbachol: A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.		2.1310ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.2510amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.2110pyrrole;
secondary amine
ethambutol
Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.		2.4110ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		4.2940glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
magnesium sulfate
Magnesium Sulfate: A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083). magnesium sulfate : A magnesium salt having sulfate as the counterion.		2.610magnesium salt;
metal sulfate;
organic magnesium salt		anaesthetic;
analgesic;
anti-arrhythmia drug;
anticonvulsant;
calcium channel blocker;
cardiovascular drug;
fertilizer;
tocolytic agent
sisomicin
Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).		3.4110amino cyclitol glycoside;
aminoglycoside antibiotic;
beta-L-arabinoside;
monosaccharide derivative
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		3.4110cephalosporinfungal metabolite
ljc 10627
biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.		2.610carbapenems;
organic sulfide;
pyrazolotriazole		antibacterial drug
oxazolidin-2-one
Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.		2.7220carbamate ester;
oxazolidinone		metabolite
clarithromycin
Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.		2.4110macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic
imipenem, anhydrous
Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.		2.610beta-lactam antibiotic allergen;
carbapenems;
zwitterion		antibacterial drug
tazobactam
Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.		3.4110penicillanic acids;
triazoles		antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor
carbapenems
[no description available]		2.4110
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		9.16409-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		7.7975aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.2510
meropenem
Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.		9.2130alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide		antibacterial agent;
antibacterial drug;
drug allergen
cefoxitin
Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.		2.610beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative		antibacterial drug
linezolid
[no description available]		9.52104acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
clindamycin
Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.		3.7120
zithromax
Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.		4.1740macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
prucalopride
prucalopride: a 5-HT4 agonist enterokinetic compound		2.2510benzamides
telavancin
telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.		7.7220glycopeptideantibacterial drug;
antimicrobial agent
istradefylline
[no description available]		2.2510oxopurine
ceftriaxone
[no description available]		3.23101,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor
cefotaxime
Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.		2.6101,3-thiazoles;
cephalosporin;
oxime O-ether		antibacterial drug;
drug allergen
pitolisant
pitolisant: functions as both inverse agonist and antagonist of histamine H3 receptors; structure in first source		2.2510organochlorine compound
tedizolid
DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.		7.7220carbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles		antimicrobial agent;
drug metabolite;
protein synthesis inhibitor
virginiamycin
Virginiamycin: A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.. virginiamycin : A mixture of cyclic polypeptide streptogramin antibiotics produced by Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. The two major components are virginiamycin M1 (also known as pristinamycin IIA) and virginiamycin S1. Virginiamycin has been widely used as a growth promotion agent in livestock and has been to have bacteriostatic activity against Gram-positive organisms such as staphylococci and streptococci.		2.3110
ly-146032
[no description available]		3.2310heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
cilastatin, imipenem drug combination
Cilastatin, Imipenem Drug Combination: Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent.		3.4110
quinupristin-dalfopristin
quinupristin-dalfopristin: RP 59500 is a combination of RP 57669 & RP 54476, which are water soluble derivatives of pristinamycin IA & pristinamycin IIB, respectively		2.3110organic molecular entity
achn 490
plazomicin: structure in first source		3.4110
mk-7655
relebactam: structure in first source		3.4110
piperidines
Piperidines: A family of hexahydropyridines.		2.2510
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		8.2650
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		10.0460
tigecycline
[no description available]		5.32140
eravacycline
eravacycline: has antibacterial activity		5.71120tetracyclines
daptomycin
[no description available]		2.3110
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Poisoning
[description not available]		02.4720
E coli Infections
[description not available]		02.0610
Group A Strep Infection
[description not available]		02.0610
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.0610
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		02.0610
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.4720
Infections, Respiratory
[description not available]		02.0710
Neutropenia
A decrease in the number of NEUTROPHILS found in the blood.		02.5220
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		02.0710
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.240
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Bacterial Skin Diseases
[description not available]		015.21396
Skin Diseases, Bacterial
Skin diseases caused by bacteria.		015.21396
Clostridioides difficile Infection
[description not available]		08.0730
Clostridium Infections
Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.		03.0730
Infections, Staphylococcal
[description not available]		04.3150
Osteomyelitis
INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.		07.4110
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		04.3150
Infections, Soft Tissue
[description not available]		08.964
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		05.5460
Soft Tissue Infections
Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)		08.964
Community Acquired Infection
[description not available]		014.77434
Bacterial Pneumonia
[description not available]		012.02204
Pneumonia, Bacterial
Inflammation of the lung parenchyma that is caused by bacterial infections.		012.02204
Diabetic Feet
[description not available]		02.4110
Infection, Wound
[description not available]		02.4110
Diabetic Foot
Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.		02.4110
Infection, Mycobacterium avium-intracellulare
[description not available]		02.4110
Mycobacterium avium-intracellulare Infection
A nontuberculous infection when occurring in humans. It is characterized by pulmonary disease, lymphadenitis in children, and systemic disease in AIDS patients. Mycobacterium avium-intracellulare infection of birds and swine results in tuberculosis.		02.4110
Acinetobacter Infections
Infections with bacteria of the genus ACINETOBACTER.		02.6920
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		02.4110
Experimental Lung Inflammation
Inflammation of any part, segment or lobe, of the lung parenchyma.		09.44100
Pneumonia
Infection of the lung often accompanied by inflammation.		09.44100
Disease, Pulmonary
[description not available]		02.920
Atypical Mycobacterial Infection, Disseminated
[description not available]		07.11150
Lung Diseases
Pathological processes involving any part of the LUNG.		02.920
Recrudescence
[description not available]		02.610
Weight Reduction
[description not available]		02.610
Weight Loss
Decrease in existing BODY WEIGHT.		02.610
Cystic Fibrosis of Pancreas
[description not available]		02.610
Cystic Fibrosis
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.		02.610
Bacterial Disease
[description not available]		06.62120
Bacterial Infections
Infections by bacteria, general or unspecified.		06.62120
Mycoplasma dispar Infection
[description not available]		02.610
Electrocardiogram QT Prolonged
[description not available]		03.9521
Long QT Syndrome
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.		03.9521
Emesis
[description not available]		04.5111
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		04.5111
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		04.5111
Infections, Legionella pneumophila
[description not available]		02.2510
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		04.3331
Infections, Coronavirus
[description not available]		02.2510
2019 Novel Coronavirus Disease
[description not available]		02.6920
Pneumonia, Viral
Inflammation of the lung parenchyma that is caused by a viral infection.		02.2510
Coronavirus Infections
Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).		02.2510
Liver Dysfunction
[description not available]		02.2510
Liver Diseases
Pathological processes of the LIVER.		02.2510
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		06.67100
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		06.67100
Bacterial Infections, Gram-Negative
[description not available]		04.0220
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		04.0220
Bacterial Infections, Gram-Positive
[description not available]		03.8630
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		02.3110
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		03.8630
Primary Peritonitis
[description not available]		02.3110
Peritonitis
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.		07.3110
Chronic Kidney Failure
[description not available]		02.1710
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		02.1710
Adverse Drug Event
[description not available]		03.0910
Infectious Skin Diseases
[description not available]		03.0910
Skin Diseases, Infectious
Skin diseases caused by bacteria, fungi, parasites, or viruses.		03.0910
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		03.0910
Bites
[description not available]		02.1710
Chlamydial Pneumonia
Pneumonia caused by infections with the genus CHLAMYDIA; and CHLAMYDOPHILA, usually with CHLAMYDOPHILA PNEUMONIAE.		02.2110
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.		08.5911
Acute Disease
Disease having a short and relatively severe course.		08.7354